Scott Gottlieb, MD 🇺🇸 (@scottgottliebmd) 's Twitter Profile
Scott Gottlieb, MD 🇺🇸

@scottgottliebmd

Senior Fellow @AEI. Partner @NEA. Contributor @CNBC. 23rd Commissioner of the @US_FDA. Public Boards: @Pfizer @Illumina @TempusAI

ID: 40156330

linkhttps://www.uncontrolledspread.com/ calendar_today15-05-2009 02:39:37

22,22K Tweet

544,544K Followers

3,3K Following

Scott Gottlieb, MD 🇺🇸 (@scottgottliebmd) 's Twitter Profile Photo

My @STATNEWS Op Ed: President Trump often touted that his first administration approved more generic drugs than any in history. He had good reason to highlight the success. Recently, however, the FDA team enabling these approvals was disbanded. It may undo that historic progress

My @STATNEWS Op Ed: President Trump often touted that his first administration approved more generic drugs than any in history. He had good reason to highlight the success. Recently, however, the FDA team enabling these approvals was disbanded. It may undo that historic progress
American Enterprise Institute (@aei) 's Twitter Profile Photo

The FDA approved a record-breaking number of generic drugs in Trump’s first term — a major win for affordable healthcare. But now, the team behind that achievement has been disbanded, threatening that historic progress, writes Scott Gottlieb, MD 🇺🇸. statnews.com/2025/05/28/fda…

Scott Gottlieb, MD 🇺🇸 (@scottgottliebmd) 's Twitter Profile Photo

My Op Ed: President Trump often touted that his first administration approved more generic drugs than any in history. He had good reason to highlight the success. Recently, the FDA team enabling these approvals was disbanded, and it may undo that historic progress. American Enterprise Institute STAT

My Op Ed: President Trump often touted that his first administration approved more generic drugs than any in history. He had good reason to highlight the success. Recently, the FDA team enabling these approvals was disbanded, and it may undo that historic progress. <a href="/AEI/">American Enterprise Institute</a> <a href="/statnews/">STAT</a>
Scott Gottlieb, MD 🇺🇸 (@scottgottliebmd) 's Twitter Profile Photo

‘At current vaccination rates, measles may become endemic again… a US simulation model predicted 51.2M measles cases over a 25-year period, 9.9M rubella cases, 4.3M poliomyelitis cases, 197 diphtheria cases, 10.3M hospitalizations, and 159,200 deaths’ jamanetwork.com/journals/jama/…

Scott Gottlieb, MD 🇺🇸 (@scottgottliebmd) 's Twitter Profile Photo

These eggs are likely still in the food supply chain, so FDA recall - and alert consumers and retailers - can reduce the risk of further illness “At least 1.7 million eggs recalled as CDC and FDA investigate multi state salmonella outbreak” nbcnews.com/health/recall/… via @nbcnews

Scott Gottlieb, MD 🇺🇸 (@scottgottliebmd) 's Twitter Profile Photo

An important step towards helping Americans incorporate healthful seafood choices into their diets in a sustainable way. This clearance demonstrates the viability of the regulatory pathway that the FDA has created for these products share.google/STW8qPgcEA8ys3…

American Enterprise Institute (@aei) 's Twitter Profile Photo

AEI's Scott Gottlieb, MD 🇺🇸 discusses the possibility that proposed cuts to NIH funding will have to be restored and potential next steps for the administration’s cost-cutting agenda.

Kevin Davies (@kevinadavies) 's Twitter Profile Photo

“The Office of Therapeutic Products of CBER played an absolutely essential role,” Urnov said... He paid tribute to Super Office Director Nicole Verdun, MD, and her staff. “They made the return of Baby KJ possible.” genengnews.com/topics/genome-…

Scott Gottlieb, MD 🇺🇸 (@scottgottliebmd) 's Twitter Profile Photo

Along with loss of other senior FDA staff, this is a significant setback for cell gene therapy. The advent of these advances was one of Pres Trump's first term triumphs, along with his efforts to expand access to them. The field now faces a harder future statnews.com/2025/06/18/top…

Zach Brennan (@zacharybrennan) 's Twitter Profile Photo

The Alliance for Regenerative Medicine said it’s “deeply disappointed” by the removal of Verdun and Anatol from OTP. IND/therapy approvals now will need sign off from CBER chief Vinay Prasad endpoints.news/fdas-top-cell-…